Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 | BPMC Stock News

3 days ago

Blueprint Medicines (BPMC, Financial) will release its Q1 2025 financial results on May 1, 2025.
The company will host a live conference call and webcast at 8:00 a.m. ET on the same day.
The webcast will be accessible for 30 days following the call.

Blueprint Medicines Corporation (BPMC), a prominent player in the biopharmaceutical sector, announced it will report its first quarter 2025 financial results on Thursday, May 1, 2025. The announcement will be made at 8:00 a.m. ET, followed by a corporate update.

Participants can join the live conference call by dialing 833-470-1428 for domestic access or 404-975-4839 for international access, using the conference ID 082088. The webcast of the call will be available in the "Events and Presentations" section on Blueprint Medicines' investor relations website.

For those unable to attend the live event, an archived version of the webcast will be accessible approximately two hours after the conference call concludes. This archived webcast will remain available for 30 days.

Blueprint Medicines is renowned for its focus on developing treatments in the areas of allergy/inflammation and oncology/hematology, with notable success in addressing systemic mastocytosis through their approved medicine AYVAKIT®/AYVAKYT® (avapritinib).

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.